Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as
adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete
radiological response after surgical resection or local ablation. The primary hypotheses of
this study are that adjuvant pembrolizumab is superior to placebo with respect to: 1)
recurrence-free survival (RFS) as assessed by blinded independent central review (BICR); and
2) overall survival (OS).
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.